NASDAQ : OABI
OmniAb, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.11 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 742.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 745.35M |
| Enterprise Value | 699.27M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 145.86M |
| Shares Outstanding | 145.86M |
| Shares Change (YoY) | +19.20% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 11.58% |
| Owned by Institutions (%) | 40.30% |
| Float | 118.24M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.54 |
| Forward PS | 32.33 |
| PB Ratio | 2.99 |
| P/TBV Ratio | 14.29 |
| P/FCF Ratio | 313.17 |
| P/OCF Ratio | 279.57 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 17.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 293.81 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.21 |
| Quick Ratio | 3.96 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | 7.62 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -16.51% |
| Return on Assets (ROA) | -7.78% |
| Return on Invested Capital (ROIC) | -8.25% |
| Return on Capital Employed (ROCE) | -13.63% |
| Weighted Average Cost of Capital (WACC) | 11.51% |
| Revenue Per Employee | $451,809 |
| Profits Per Employee | -$488,461 |
| Employee Count | 89 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -405,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.37 |
| 52-Week Price Change | +247.62% |
| 50-Day Moving Average | 4.65 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 58.66 |
| Average Volume (20 Days) | 1,385,170 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.54M |
| Short Previous Month | 8.20M |
| Short % of Shares Out | 5.86% |
| Short % of Float | 7.23% |
| Short Ratio (days to cover) | 6.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 40.21M |
| Gross Profit | 39.27M |
| Operating Income | -37.36M |
| Pretax Income | -43.88M |
| Net Income | -43.47M |
| EBITDA | -20.31M |
| EBIT | -37.36M |
| Loss Per Share | -$0.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 64.21M |
| Total Debt | 18.14M |
| Net Cash | 46.07M |
| Net Cash Per Share | $0.32 |
| Equity (Book Value) | 249.16M |
| Book Value Per Share | 1.71 |
| Working Capital | 54.13M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 2.67M |
| Capital Expenditures | -286,000 |
| Depreciation & Amortization | 17.05M |
| Net Borrowing | n/a |
| Free Cash Flow | 2.38M |
| FCF Per Share | $0.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 97.65% |
| Operating Margin | -92.91% |
| Pretax Margin | -109.12% |
| Profit Margin | -108.11% |
| EBITDA Margin | -50.50% |
| EBIT Margin | -92.91% |
| FCF Margin | 5.92% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.20% |
| Shareholder Yield | -19.20% |
| Earnings Yield | -6.62% |
| FCF Yield | 0.32% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.33 |
| Price Target Difference | 63.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 55.26% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.66 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |